STAGE IIIA CUTANEOUS MELANOMA AJCC V7

This early-phase trial tested the safety and best dose of two drugs—riluzole and sorafenib—given together to people with advanced solid tumors or melanoma that had spread and stopped responding to standard treatments. The goal was to find the highest safe dose and see if the comb…

This early-phase study tests whether giving patients with advanced melanoma their own genetically modified T-cells, followed by high-dose interleukin-2, is safe and feasible. The T-cells are altered in the lab to resist a protein that normally stops them from attacking tumors. Ab…

This study tested two different doses of the immunotherapy drug ipilimumab, either alone or combined with high-dose interferon, in 88 people with advanced melanoma that could not be surgically removed. The goal was to see if the combination could delay cancer growth better than i…

This early-phase trial tests the safety and best dose of two drugs—MK-2206 and hydroxychloroquine—given together to people with advanced solid tumors, melanoma, prostate, or kidney cancer. The goal is to see if blocking certain cell signals and a process called autophagy can slow…

This study tested whether adding a drug called GM-CSF (sargramostim) to the immunotherapy ipilimumab helps people with advanced melanoma that cannot be removed by surgery. About 245 participants received either the combination or ipilimumab alone. The main goal was to see if the …

This early-phase study tests a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system fight cancer) and ibrutinib (which blocks certain enzymes cancer cells need to grow)—in people with advanced melanoma that cannot be removed by surgery. The main g…